Abstract | BACKGROUND: AIMS: This study investigated long-term ADV treatment in HBeAg-positive patients. METHODS: A total of 480 Chinese subjects with HBeAg-positive CHB who participated in a 1-year, double-blind, placebo-controlled study of ADV 10 mg daily were offered open-label continuation for a further 208 weeks. RESULTS: A total of 390 subjects completed 5 years of treatment. Baseline median hepatitis B virus (HBV) DNA was 8.8 log(10) copies/ml and alanine aminotransferase (ALT) 2.6 × upper limit of normal. Treatment with ADV resulted in sustained suppression of median HBV DNA by 4.8, 5.0, 5.1, 5.4 and 5.5 log(10) copies/ml after 1, 2, 3, 4 and 5 years respectively. Continuous treatment with ADV led to a progressive increase in the proportion of subjects achieving undetectable HBV DNA, from 28% after 1 year to 58% after 5 years. HBeAg seroconversion rates increased cumulatively from 11% after 1 year to 29% after 5 years. HBsAg seroconversion was achieved by 1.0% of patients. ADV resulted in ALT normalization that was maintained throughout this study in 75-79% of subjects. Virological breakthrough associated with ADV resistant mutations (rtN236T and rtA181V) occurred in 14.6% of subjects. ADV was well tolerated. CONCLUSION: Five years of ADV treatment in Chinese subjects with HBeAg-positive CHB resulted in increasing virological and serological responses and sustained biochemical responses over time. Virological resistance was identified in 14.6% of patients. Urgent switch or add-on therapy with a nucleoside analogue is necessary if ADV resistant mutations are detected, particularly rtN236T. Treatment was well tolerated.
|
Authors | Zeng Minde, Mao Yimin, Yao Guangbi, Hou JinLin, Wang Hao, Ren Hong, Wang Yuming, Zhou Xiaqiu, Xu Daozhen, Chen Yagang, Niu Junqi, Chen Youming, Wang Yaozong, Jonathan Dixon, Keith Barker |
Journal | Liver international : official journal of the International Association for the Study of the Liver
(Liver Int)
Vol. 32
Issue 1
Pg. 137-46
(Jan 2012)
ISSN: 1478-3231 [Electronic] United States |
PMID | 22097972
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2011 John Wiley & Sons A/S. |
Chemical References |
- Antiviral Agents
- DNA, Viral
- Hepatitis B e Antigens
- Organophosphonates
- Adenine
- adefovir dipivoxil
|
Topics |
- Adenine
(analogs & derivatives, therapeutic use)
- Adolescent
- Adult
- Antiviral Agents
(therapeutic use)
- Asian People
- DNA, Viral
(analysis)
- Drug Resistance, Viral
(genetics)
- Female
- Hepatitis B e Antigens
(blood)
- Hepatitis B virus
(genetics, immunology)
- Hepatitis B, Chronic
(diagnosis, drug therapy, virology)
- Humans
- Liver Function Tests
- Male
- Middle Aged
- Mutation
(drug effects)
- Organophosphonates
(therapeutic use)
- Treatment Outcome
- Viral Load
(drug effects)
- Viremia
(drug therapy)
- Young Adult
|